BACKGROUND AND AIMS: @entity1702 ( @entity1702 ) have been used for the palliative treatment of malignant @entity1084 ( @entity1084 ). The aim of this study was to evaluate the clinical outcomes of salvage @entity1702 for stent malfunction and to identify the prognostic factors for a longer patency. METHODS: A total of 108 @entity1 who underwent a secondary salvage @entity1702 placement for a primary stent malfunction were retrospectively reviewed at the Seoul National University Hospital between August 2004 and May 2013. The duration of patency for salvage @entity1702 was defined as the time between salvage @entity1702 placement and the recurrence of obstructive symptoms that were confirmed either endoscopically or radiologically. RESULTS: The technical and clinical success rates for salvage @entity1702 were 100 and 82.4  % (95  % confidence interval [CI] 74.0-89.0), respectively. A salvage @entity1702 malfunction occurred in 29 (26.9  %) of the 108 @entity1 . The median duration of patency for salvage @entity1702 was 59.5  days (range 3-928, 95  % CI 73.7-118.3). Longer @entity1702 patencies of more than 60  days were significantly associated with palliative chemotherapy (odds ratio  =  2.539, 95  % CI 1.031-6.252, p  =  .043). For salvage @entity1702 , covered-uncovered stents had a longer patency duration, as compared with other combinations of primary and salvage stent types. CONCLUSIONS: Longer patency durations for salvage @entity1702 were associated with palliative chemotherapy after salvage @entity1702 insertion. Salvage @entity1702 could be a feasible and effective treatment for primary stent malfunction in malignant @entity1084 .

Clinical outcomes of re-stenting in XXXX with stent malfunction in malignant @entity1084 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1084 :: ('MESH:D017219', 'Disease') :: ['gastric outlet obstruction', 'GOO'] @entity1702 :: ('MESH:D013651', 'Disease') :: ['SEMS', 'Self-expanding metal stents']
@entity1 :: (9606,Species) :: ['patients']
